Investment Rating - The report assigns a positive investment rating to the company, indicating a favorable outlook for future performance [4]. Core Insights - The company is one of the top global automotive parts suppliers, with a strong traditional business that supports performance growth. It has expanded into battery boxes, smart exteriors, and chassis components, accelerating its transition to electric and intelligent vehicles [4]. - Emerging businesses such as robotics, low-altitude flight, and wireless charging for vehicles are market hotspots, with new products expected to be mass-produced by 2025 or 2026, contributing to revenue [4]. - The company is expected to resume dividend payments after a hiatus in 2023 due to high capital expenditures and debt levels. It is transitioning from an expansion phase to a harvesting phase, with improved cash flow and stock buybacks anticipated [4]. - Projected net profits for 2024-2026 are 2.2 billion, 2.51 billion, and 3.15 billion, respectively, with corresponding P/E ratios of 11.3x, 9.9x, and 7.9x, indicating a currently low valuation [4]. Company Overview - The company has over 30 years of experience in the automotive parts industry, with a global presence. Founded in 1992 and listed in Hong Kong in 2005, it is the largest supplier of battery boxes and body structure parts globally, employing over 20,000 people across 77 factories and offices in 14 countries [9][10]. Financial Performance - The company has shown resilient revenue growth since its listing, with a 13.8% year-on-year increase in revenue to 11.09 billion in the first half of 2024, and a 20.4% increase in net profit to 1.07 billion [18][22]. - The gross profit margin and net profit margin have improved slightly in the first half of 2024, with figures of 28.5% and 9.7%, respectively [22]. Revenue Structure - The company has seen a continuous increase in overseas market share, with overseas revenue accounting for 59.2% of total revenue in the first half of 2024. The Americas and Europe represent significant portions of this revenue [26]. - The traditional business, including metal trims, plastic parts, and aluminum components, constitutes 67% of revenue, while new businesses like battery boxes account for 33% [29]. Emerging Business Development - The company has a strong order backlog of 236 billion, with over 53% of orders related to battery boxes, indicating significant growth potential in this area [31]. - The company has established a research center focused on automotive intelligent integration components and lightweight technology, leading to innovations in various sectors, including robotics and low-altitude flight [33][36].

港股晨报 2025 年 3 月 12 日 国证国际证券（香港）有限公司 • 研究部 1. 国证视点：资金流入增强港股面对美股波动的免疫力 1. 国证视点 资金流入增强港股面对美股波动的免疫 力 2. 行业点评 港股昨日展示了强劲的韧性，低开高走。隔晚美股暴挫，恒指大幅低开 508 点 至 23274 点，最低曾跌 545 点至 23238 点。低位大量买盘涌现，大市逐步收 复失地，尾盘曾倒升 75 点至 23858 点，收市才略为回软。恒指收报 23782 点， 全日微跌 1 点或 0.01%。恒生科指报捷，升 1.39%。大市交投略为回升，主板 成交报 3070 亿港元，较上日多 1.73%。 大市急挫之际，港股通资金大幅涌入扫货。北水昨日净流入逾 296 亿元，较上 日增加 144.6%。水净买入最多的个股依次是盈富基金 2800.HK、恒生中国企 业 2828.HK、阿里 9988.HK；净卖出最多的依次是中芯 981.HK、金蝶国际 268.HK。 行业表现方面，12 个恒生综合行业指数中，9 个上升 3 个下跌。领涨板块为必 需性消费、医疗保健及资讯科技，涨幅分别为 2.68%、1.42%及 0.9 ...

Investment Rating - The report suggests a positive outlook for the beauty and medical aesthetics industry, highlighting strong performances from specific companies during the promotional period [4]. Core Insights - The report emphasizes the resilience of domestic brands in the beauty sector, with a stable market share of 25% for domestic brands on Tmall compared to the previous year [2]. - Notable performances include Proya, which maintained its top position, and Juzibio, which improved its ranking significantly on Tmall [2]. - On Douyin, the beauty category's GMV reached over 11.3 billion yuan, marking a 72% increase from the previous year, with skincare and makeup categories showing substantial growth [3]. Summary by Sections Tmall Platform - The top four brands maintained their positions, with domestic brands holding a 25% market share, consistent with the previous year [2]. - Proya ranked first, while Juzibio's Kefu Mei moved up five places to eighth, driven by strong sales of its collagen products [2]. - Maogeping entered the top 20 for the first time, with significant sales from its caviar mask and cushion foundation [2]. Douyin Platform - The beauty category's GMV exceeded 11.3 billion yuan, a 72% increase year-on-year [3]. - Skincare products generated over 8.4 billion yuan, with a 65% increase from the previous year, while the makeup category saw a 106% growth, reaching over 2.4 billion yuan [3]. - Maogeping's makeup sales reached between 50 million to 75 million yuan, significantly improving its market position [3]. Overall Market Performance - Companies such as Juzibio, Maogeping, and Proya showed exceptional performance during the promotional period, indicating strong market dynamics [4].

SDICSI 2025 年 3 月 10 日 石油行业动态点评 OPEC 预计 Q2 重启增产，国际油价向下破 70 美元 美国能源信息署（EIA）公布 2 月 28 日当周原油库存情况，EIA 美国商业原油库 存为 433.8 百万桶，较前周+3.6 百万桶，远超市场预期的 34.1 百万桶，供应过 剩压力有所加剧；同时受到成品油出口增长，汽油与馏分油库存均有所下降。3 月 3 日 OPEC+成员国会议中重申了预计于 Q2 逐步退出 220 万桶/日的减产计 划，短期内石油价格下行压力变大，此外仍需关注美国对于伊朗的制裁预期，以 及需要关注东亚国家的需求增长是否超预期。 报告摘要 OPEC+增产形成下行压力，仍需关注其他因素。根据最新会议报道，OPEC+组 织预计将于 4 月 1 日开始提高石油产量，此次增产是 OPEC+自 2022 年以来的 首次，同时这也是近期美国关于希望降低油价对 OPEC 以及沙特施压后所做出的 决定。根据行业测算，此次增长规模约为 13.8 万桶/日。目前看增产大概率会势 在必行，但仍需等待 3 月底的会议是否会有进一步调整，此外美国对于伊朗的制 裁预期或可对油价形成一定支撑，以 ...

Market Overview - The report highlights a structural shift in the market, indicating an "East rises, West declines" trend, presenting operational opportunities [1][9]. - Recent volatility in the US stock market is noted, with the S&P 500 and NASDAQ both experiencing declines of 3% and 3.3% respectively over the past week [9]. Economic Indicators - US employment data shows weakness, with the ADP report indicating an increase of only 77,000 jobs in February, significantly below market expectations of 146,000 [13]. - The Challenger report reveals a year-on-year increase in announced layoffs by 103%, reaching 172,000, the highest since July 2020 [13]. - The ISM manufacturing PMI for February stands at 50.3, slightly below expectations, with employment indices indicating contraction [18]. Interest Rate Trends - The report discusses a rise in panic sentiment leading to a decline in interest rates, with the 10-year Treasury yield dropping to 4.2% [26]. - The expectation for interest rate cuts has increased from 1.2 to 3 times this year, reflecting concerns over economic slowdown [26]. Hong Kong Market Insights - The report emphasizes the positive impact of the "Two Sessions" on the Hong Kong stock market, with a focus on stimulating the digital economy and technology sectors [32]. - The government aims for a GDP growth target of around 5% for 2025, with increased fiscal deficit to support economic resilience against trade tensions [32]. Upcoming Focus - The report indicates that market attention will be on upcoming inflation data, with expectations for the core CPI to show a month-on-month increase of 0.3% [34]. - The focus on technology and consumption sectors is expected to drive market performance, particularly in Hong Kong, amidst ongoing trade war concerns [34].

Investment Rating - The report maintains a "Buy" rating for China Tobacco Hong Kong with a target price raised to HKD 29.2, indicating a potential upside of 19% from the current stock price of HKD 24.85 [1][5][7]. Core Insights - China Tobacco Hong Kong reported a revenue of HKD 13,074.2 million for the year, representing a year-on-year growth of 10.5%, and a net profit of HKD 902.8 million, which is a 30.4% increase compared to the previous year [1][5]. - The company expects net profits for the years 2025, 2026, and 2027 to be HKD 9.6 billion, HKD 10.2 billion, and HKD 10.8 billion respectively, with corresponding EPS of HKD 1.32, HKD 1.40, and HKD 1.48 [1][5]. Revenue and Profit Analysis - The tobacco leaf import business showed steady growth, achieving a revenue of HKD 8.254 billion in 2024, up 2.2% year-on-year, with a gross profit of HKD 826 million, reflecting a 12.7% increase [2]. - The gross margin for tobacco leaf imports was 10.0%, an increase of 0.9 percentage points year-on-year, primarily due to a higher proportion of higher-margin Brazilian business [2]. - The cigarette export segment saw a revenue of HKD 1.574 billion in 2024, a 30.2% increase, with a gross profit of HKD 277 million, marking a 69.1% rise [3]. - The gross margin for cigarette exports improved to 17.6%, up 4.0 percentage points year-on-year, benefiting from a higher proportion of self-operated channels [3]. Product Segmentation - The export of tobacco leaf products generated HKD 2.062 billion in revenue, a 24.8% increase, with a gross profit of HKD 84 million, up 85.8% [3]. - New tobacco product exports achieved a revenue of HKD 135 million, a 4.0% increase, with a gross profit of HKD 7 million, reflecting a 23.2% growth [4]. - The Brazilian business segment reported a revenue of HKD 1.050 billion, a 37.0% increase, with a gross profit of HKD 184 million, up 30.2% [4]. Dividend and Shareholder Information - The company declared a final dividend of HKD 0.31 per share, with a total annual dividend of HKD 0.46 per share, resulting in a payout ratio of 37% and a dividend yield of 1.9% based on the current stock price [4][5]. Financial Projections - The report projects revenue growth rates of 0.5%, 4.0%, and 3.5% for the years 2025, 2026, and 2027 respectively, with net profit growth rates of 6.4%, 6.3%, and 5.4% for the same periods [11][13]. - The estimated gross margin is expected to improve gradually, reaching 11.57% by 2027 [11][13].

Investment Rating - The investment rating for the company is 5.4, based on operational performance, industry outlook, valuation, and market sentiment [8]. Core Insights - The company, Chifeng Jilong Gold Mining Co., Ltd., is a rapidly growing international gold producer with a significant increase in gold production from 2021 to 2023, achieving a compound annual growth rate (CAGR) of 33.1% [1]. - The company has a strong operational efficiency, with all-in sustaining costs below the global average, ranking fifth among Chinese gold producers and 20-30 globally [1]. - The revenue for the company has shown a steady increase, with a 17.8% year-on-year growth for the nine months ending September 30, 2024, driven by higher average selling prices and increased sales volume [2]. - The global gold demand is expected to grow at a CAGR of 0.8% from 2024 to 2028, with central bank demand growing the fastest at 6.9% [3]. - The company is positioned as the largest private gold producer in China, with a robust market outlook and a strong track record in mergers and acquisitions [5]. Company Overview - Chifeng Jilong Gold Mining Co., Ltd. operates six gold and multi-metal mines across China, Laos, and Ghana, with a total gold production of 461.5 thousand ounces in 2023 [1]. - The company’s revenue is primarily derived from gold mining, accounting for 87.6% of total revenue in 2023, with Laos and Ghana being the largest revenue sources [2]. - The company has a unique corporate culture and incentive mechanisms that drive continuous growth among management and employees [5]. Financial Performance - The company's revenue for the years 2021, 2022, and 2023 were 37.8 billion, 62.6 billion, and 72.2 billion CNY respectively, with a gross margin of 32.6% in 2023 [2]. - The net profit attributable to shareholders for the same years was 5.8 billion, 4.5 billion, and 8.0 billion CNY, indicating a strong recovery in profitability [2]. Market Conditions - The global gold spot price is projected to rise at a CAGR of 7.1% from 2024 to 2028, reflecting strong demand [4]. - The company’s IPO price range is set between 13.72 and 15.83 HKD, with a total market capitalization estimated at 256.50 to 295.95 billion HKD post-IPO [11].

Investment Rating - The report suggests a positive outlook for the pharmaceutical industry, emphasizing the importance of innovation and public hospital reforms [2][3]. Core Insights - The 2025 government work report highlights the need to strengthen basic healthcare services and improve social security policies, indicating a supportive environment for the pharmaceutical sector [1][3]. - Key measures include the establishment of an innovation drug catalog, optimization of drug procurement policies, and a focus on public hospital reforms aimed at enhancing service quality [2][3]. - Increased fiscal support for healthcare, particularly in elderly medicine and innovation, aligns with the upcoming implementation of the Class B medical insurance catalog and the expansion of commercial insurance coverage [3]. Summary by Sections Government Initiatives - The government aims to enhance basic healthcare services and deepen public hospital reforms, with a focus on quality improvement [3]. - There will be further relaxation of foreign investment market access and expansion of pilot programs in the healthcare sector [3]. Financial Support - The per capita financial subsidy for resident medical insurance will increase from 670 yuan to 700 yuan, benefiting 320 million people [3]. - The per capita financial subsidy for basic public health services will rise to 99 yuan [3]. Investment Opportunities - The report identifies potential investment opportunities in the following sectors: - Innovative pharmaceuticals: Kelun-Botai Biological (6990.HK), BeiGene (6160.HK/688235.SH/ONC.US) [3]. - Traditional Chinese medicine: Gushengtang (2273.HK) [4]. - AI in healthcare: Jingtai Holdings-P (2228.HK), MicroPort Scientific-B (2252.HK) [4].

汪阳Alex Wang(中央編號：BIT765) 王强 Jimmy Wang(中央編號：BGJ404) 请参阅本报告尾部免责声明 行业催化：2025年为人形机器人量产元年 港股机器人产业链解读与投资机会梳理 国证国际证券(香港)有限公司 • 研究部 2025年2月27日 2 企业 产品 量产时间 目标产能 核心场景 特斯拉 Optimus Gen2 2025Q4 1万台/年 汽车工厂装配、家 庭服务 优必选 Walker S1 2025Q2 5万台/年 工业质检、物流搬 运 Figure AI Figure 02 2025Q3 3万台/年 仓储管理、零售服 务 宇树科技 Unitree G1 2025Q1 2万台/年 消费级教育、安防 巡逻 三星电子 （未命名） 2025H2 1万台/年 医疗护理、酒店服 务 资料来源：互联网公开资料，国证国际研究整理 Unitree G1 Figure 02 Optimue-Gen2 优必选 Walker S 资料来源：公开资料，国证国际研究整理 2025/2/28 请参阅本报告尾部免责声明 2 Ø 成本下降曲线：2023年特斯拉Optimus原型机单台成本＞50万美元；工 ...

SDICSI 2025 年 2 月 24 日 恒指及港股通名单观察 恒生指数成分股没变动，但仍需关注组合比重重整带来的波动。恒生指数有限公 司于周五公布 Q4 指数成分股检讨结果，结果将于 3 月 10 日生效。恒生指数 （HSI）成分股没有变动，成分股数目维持 83 只。 不过，即使恒生指数没有成分股变动，我们要注意个别指数成分股的比重仍会有 较大变动。这是因为恒生指数成分股的比重上限设定为 8%，重磅股的比重将在 季度检讨生效时重设为 8%（见附录一）。 截至 2 月 19 日，阿里巴巴 9988.HK、腾讯 700.HK、汇控 0005.HK 的比重为 10.12% / 8.48% / 8.28%，将会于生效日调低至 8%，对应比重减幅为 2.12 / 0.48 / 0.28 个百分点，阿里巴巴所受的影响最大。 因应上述三个股份的比重降低，其他成分股的比重普遍上升，其中工行 1398.HK 因为流通系数上调（从 90%升至 95%），其比重由 3.01%升至 3.31%，升幅达 0.30 个百分点。 由于市场有不少被动基金及 ETF 如盈富基金 2800.HK（市值约 1680 亿港元）追 踪恒生指数， ...